Trump to visit Fed on Thursday amid Powell feud, renovation probe
Investing.com - Cantor Fitzgerald maintained its Overweight rating on Kura Oncology (NASDAQ:KURA) following a webinar with the company’s leadership team. The stock, currently trading at $5.80, has fallen significantly from its 52-week high of $23.48, with InvestingPro analysis suggesting the shares are currently undervalued.
The investment firm hosted Kura executives on Wednesday to discuss recent data updates for ziftomenib, the company’s menin inhibitor treatment for acute myeloid leukemia (AML), presented at the ASCO and EHA conferences.
The discussion centered on pre-launch activities for ziftomenib in NPM1-mutated relapsed/refractory AML, with a PDUFA date of November 30, 2025, as well as expectations for initial first-line combination data with azacitidine and venetoclax by year-end 2025.
Cantor Fitzgerald noted that investor uncertainty regarding the market size for menin inhibitors and competitive dynamics among three players in the space has affected Kura’s share price.
The firm suggested that as menin inhibitors approach potential launches later this year, including revumenib from Syndax and ziftomenib from Kura, targeting NPM1 mutations that represent approximately 30% of AML cases, more concrete data points may emerge to better estimate the market opportunity.
In other recent news, Kura Oncology has been the focus of several analyst updates following significant clinical trial results. H.C. Wainwright reiterated its buy rating with a $40 price target after Kura’s presentation at the European Hematology Association meeting, highlighting the promising results from the KOMET-007 trial. This trial evaluated ziftomenib combined with standard chemotherapy in patients newly diagnosed with acute myeloid leukemia (AML) and demonstrated high rates of complete response and minimal residual disease negativity. Similarly, Citizens JMP maintained a Market Outperform rating with a $28 price target, noting the potential for regulatory approval of ziftomenib in the fourth quarter of 2025. The U.S. Food and Drug Administration (FDA) has accepted Kura’s New Drug Application for ziftomenib, granting it priority review with a Prescription Drug User Fee Act (PDUFA) date set for November 30, 2025. Leerink Partners also reiterated its Outperform rating with a $23 target, emphasizing the favorable benefit-risk profile of ziftomenib. Kura Oncology plans to initiate pivotal Phase 3 trials in the second half of 2025, supported by a strong pro forma cash position of $703.2 million. These developments underline Kura’s ongoing efforts to advance its treatment pipeline and secure regulatory approvals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.